Rongkui Luo
Overview
Explore the profile of Rongkui Luo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
460
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang N, Shao X, Xu L, Zhu W, Wang H, Luo R, et al.
BMC Cancer
. 2025 Mar;
25(1):465.
PMID: 40082810
Objective: To investigate associations between breast cancer molecular subtype and intravoxel incoherent motion imaging (IVIM) and amide proton transfer-weighted (APTw). Methods: This prospective study involved 264 patients with suspected breast...
2.
Zhao S, Liu X, Luo R, Jian Z, Xu C, Hou Y, et al.
Cell Death Differ
. 2025 Feb;
PMID: 39987355
Dysregulation of the MDM2-p53 pathway is a commonly observed phenomenon in cancer, where overexpression or amplification of MDM2 leads to increased degradation of p53. This results in reduced levels of...
3.
Zhang F, Wang Y, Zhu J, Wang J, Li Q, Feng J, et al.
Mol Cell Proteomics
. 2025 Feb;
:100922.
PMID: 39921206
The heart is a vital muscular organ in vertebrate animals, responsible for maintaining blood circulation through rhythmic contraction. Although previous studies have investigated the heart proteome, the full hierarchical molecular...
4.
Jiang J, Pang Y, Luo R, Wei Y, Zhang J, Li M, et al.
J Endocrinol Invest
. 2024 Dec;
PMID: 39636472
Purpose: Pheochromocytomas and paragangliomas (PPGLs) exhibit the highest degree of heritability among all human tumors, yet the genetics of urinary bladder paragangliomas (UBPGLs) remains poorly understood. The present study aims...
5.
Zhou Q, You Y, Zhao Y, Xiao S, Song Z, Huang C, et al.
Cell Oncol (Dordr)
. 2024 Nov;
PMID: 39612152
Purpose: Leiomyosarcoma (LMS) is an aggressive mesenchymal malignant tumor with poor therapeutic options, but the molecular mechanisms underlying LMS remain largely unknown. Increasing evidence indicates that transient receptor potential vanilloid...
6.
Relationship between [F]FDG PET/CT findings and claudin 18.2 expression in metastatic gastric cancer
Yin H, Luo R, Lv J, Mao W, Shi H
Eur Radiol
. 2024 Nov;
PMID: 39572448
Aim: Given that claudin 18.2 (CLDN18.2) is a cell surface protein specifically expressed by gastric cancer cells, anti-CLDN18.2 antibodies have demonstrated significant antitumor effects in patients with advanced gastric adenocarcinoma....
7.
Min L, Liu Z, Zhou B, Zhou P, Luo R, Ding Y, et al.
Cancer Med
. 2024 Nov;
13(21):e70396.
PMID: 39499047
Purpose: The feasibility of transarterial infusion chemotherapy and embolization (TAICE) in the treatment of advanced gastric cancer remains unclear. This study explored the value of TAICE in patients with unresectable...
8.
Wu G, Luo R, Xu Q, Yang L, Xia H, Chew V, et al.
Virchows Arch
. 2024 Oct;
485(5):913-923.
PMID: 39384623
Tumor budding (TB) has been associated with poor survival in a variety of cancers including intrahepatic cholangiocarcinoma (iCCA). As tumor histomorphological features are significantly altered after neoadjuvant therapy (NAT), our...
9.
Deng M, Liu X, Jiang Y, Luo R, Xu L, Zhang X, et al.
World J Surg Oncol
. 2024 Oct;
22(1):261.
PMID: 39350287
To date, there have been no reports on tertiary lymphoid structures (TLS) in primary adenocarcinoma of jejunum and ileum. In this study, we employed digital pathology image analysis software to...
10.
Xie T, Gao Y, Hu J, Luo R, Guo Y, Xie Q, et al.
Endocrine
. 2024 Sep;
87(1):281-294.
PMID: 39240459
Purpose: Pituitary neuroendocrine tumors (PitNETs) with invasion of the cavernous sinus (CS) are particularly challenging to treat. Tumor associated fibroblasts (TAFs) are recognized for their pivotal role in reprogramming extracellular...